CI-921 : a clinical, pharmacokinetic and metabolic study of a potential new cytotoxic agent

Summary

CI-921 : a clinical, pharmacokinetic and metabolic study of a potential new cytotoxic agent is a doctoral thesis^[1].

Key Facts

• CI-921 : a clinical, pharmacokinetic and metabolic study of a potential new cytotoxic agent authored a clinical, pharmacokinetic and metabolic study of a potential new cytotoxic agent — author (P50): Janet R Hardy^[2].
• CI-921 : a clinical, pharmacokinetic and metabolic study of a potential new cytotoxic agent's instance of is recorded as a clinical, pharmacokinetic and metabolic study of a potential new cytotoxic agent — instance of (P31): doctoral thesis^[3].
• CI-921 : a clinical, pharmacokinetic and metabolic study of a potential new cytotoxic agent's publisher is recorded as a clinical, pharmacokinetic and metabolic study of a potential new cytotoxic agent — publisher (P123): ResearchSpace@Auckland^[4].
• CI-921 : a clinical, pharmacokinetic and metabolic study of a potential new cytotoxic agent's country of origin is recorded as a clinical, pharmacokinetic and metabolic study of a potential new cytotoxic agent — country of origin (P495): New Zealand^[5].
• CI-921 : a clinical, pharmacokinetic and metabolic study of a potential new cytotoxic agent's publication date is recorded as +1989-00-00T00:00:00Z^[6].
• CI-921 : a clinical, pharmacokinetic and metabolic study of a potential new cytotoxic agent's main subject is recorded as a clinical, pharmacokinetic and metabolic study of a potential new cytotoxic agent — main subject (P921): family medicine^[7].
• CI-921 : a clinical, pharmacokinetic and metabolic study of a potential new cytotoxic agent's work available at URL is recorded as https://researchspace.auckland.ac.nz/handle/2292/5507^[8].
• CI-921 : a clinical, pharmacokinetic and metabolic study of a potential new cytotoxic agent's Handle ID is recorded as 2292/5507^[9].
• CI-921 : a clinical, pharmacokinetic and metabolic study of a potential new cytotoxic agent's title is recorded as CI-921 : a clinical, pharmacokinetic and metabolic study of a potential new cytotoxic agent^[10].
• CI-921 : a clinical, pharmacokinetic and metabolic study of a potential new cytotoxic agent's copyright holder is recorded as a clinical, pharmacokinetic and metabolic study of a potential new cytotoxic agent — copyright holder (P3931): Janet R Hardy^[11].
• CI-921 : a clinical, pharmacokinetic and metabolic study of a potential new cytotoxic agent's thesis submitted to is recorded as a clinical, pharmacokinetic and metabolic study of a potential new cytotoxic agent — thesis submitted to (P4101): University of Auckland^[12].
• CI-921 : a clinical, pharmacokinetic and metabolic study of a potential new cytotoxic agent's on focus list of Wikimedia project is recorded as a clinical, pharmacokinetic and metabolic study of a potential new cytotoxic agent — on focus list of Wikimedia project (P5008): NZThesisProject^[13].
• CI-921 : a clinical, pharmacokinetic and metabolic study of a potential new cytotoxic agent's copyright status is recorded as a clinical, pharmacokinetic and metabolic study of a potential new cytotoxic agent — copyright status (P6216): copyrighted^[14].
• CI-921 : a clinical, pharmacokinetic and metabolic study of a potential new cytotoxic agent's online access status is recorded as a clinical, pharmacokinetic and metabolic study of a potential new cytotoxic agent — online access status (P6954): open access^[15].
• CI-921 : a clinical, pharmacokinetic and metabolic study of a potential new cytotoxic agent's thesis committee member is recorded as a clinical, pharmacokinetic and metabolic study of a potential new cytotoxic agent — thesis committee member (P9161): Bruce Charles Baguley^[16].

Body

Designation and Status

CI-921 : a clinical, pharmacokinetic and metabolic study of a potential new cytotoxic agent's instance of is recorded as a clinical, pharmacokinetic and metabolic study of a potential new cytotoxic agent — instance of (P31): doctoral thesis^[3].